about
Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling.Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study.Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomasPulmonary manifestations of Sjögren's syndrome.Central and peripheral neurological complications of primary Sjögren's syndrome.Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).Adherence to online monitoring of patient-reported outcomes by patients with chronic inflammatory diseases: a feasibility study.Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes.Involvement and prognosis value of CD8(+) T cells in giant cell arteritis.Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients.[Fever and persistent cough in a 65-year-old patient].[Abrupt onset of papulovesicular lesions: diagnostic features and outcome].[A dog's life!...latent syphilis].Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.Active immunological profile is associated with systemic Sjögren's syndrome.[DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome after sulfasalazine and carmazepine: report of two cases].Inflammasome activation restricts Legionella pneumophila replication in primary microglial cells through flagellin detection.[Psychiatric complications of corticoid therapy in the elderly over 65 years of age treated for Horton disease].Interleukin-1 blockade in refractory giant cell arteritis.[Rare opportunistic infection due to Leuconostoc].[Polymyositis induced or associated with lipid-lowering drugs: five cases].Immunological profiles determine neurological involvement in Sjögren's syndrome.18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome.Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients.Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome.[Cogan syndrome or sarcoidosis?].Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.[Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].Primary Sjogren's syndrome in men.Is rituximab an effective treatment of refractory calcinosis?Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.Étude de l'influence d'une hypergammaglobulinémie sur le titre des anticorps antiphospholipidesEuropean League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome PatientsPhysiopathologie du syndrome de Gougerot-Sjögren primitifNeuropathie des petites fibres au cours du syndrome de Sjögren primitifSyndrome des antiphospholipides avec anticorps antiphosphatidyléthanolamine isolés : à propos de 20 casPregnancy and primary Sjögren’s syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies
P50
Q34761856-70740651-66C3-4504-B2C8-A9AEECF64D43Q34873101-955B26C7-6B00-4F73-9A98-629468768B0FQ35041314-B4B9E4F7-1F9B-453D-8D64-3D37F290931DQ35774612-BC3F2D64-9B19-4D7B-8BB5-27C8DCC37AE4Q36081364-27A6C9C8-9E78-4C57-94DE-D6C85FB72E48Q37824943-7BDB1C87-1671-41F4-8088-7C6B6332DC79Q38030161-17E694B8-BEBD-432F-9A03-9741B526165EQ38718798-AFA9EAEF-FA60-4772-957B-E7A21CB0DB0BQ39007658-CAA76C1E-AD1D-42F7-8857-1E8875CCD3BCQ39251679-D86973AB-2A68-41A4-8067-1401A166A169Q39728354-56D8D2D6-D00A-46AF-8F1A-589F9E2F0987Q40107745-50E3CA7C-C965-4AD2-94B1-1F80ADE4A58DQ40276588-FE6F5A61-E7B9-4464-9215-C40CCD1DFD12Q40462993-8DA5544A-992F-4ACF-BFE2-E37ECC5A9B0CQ40600500-5F85E6C6-4632-47DA-B47C-0765F6242F47Q41905224-311924B8-60BF-4175-8254-26F7A8C8F100Q41936333-E3410D51-392D-4CD8-9A13-064D758B96B6Q43545216-DFECE184-F03D-4877-BE53-CC9333FA9039Q43658958-57075854-85B3-4490-B53A-EE3B9526B381Q44197929-773E1A5D-A580-496B-AE76-FA9A07CAB861Q44214034-40DC8C78-05A9-446A-BA11-6DDEDCAFA46EQ44281655-8010A798-313C-4DB8-A9C7-0CCD50B75D71Q44411016-E72E39F6-CF02-4906-ADD6-DEBD798DFC5FQ44819388-5C8B66F8-84A8-4D7F-B93F-8B10420143B6Q45736006-45C41698-7852-47F4-A900-64508016C582Q45773785-C9DDEB34-0C0F-4D72-BC83-7E6A21E4D8ADQ47398038-E172F08B-0FD4-462F-84CA-FD29B4C92F98Q48897306-B98DC862-B99D-46B0-BD4F-DC9C843E7F72Q50486271-2535D4C2-26AC-4CA0-BCF5-40D32BF267D7Q50568686-A419D404-17F8-464C-A003-E19431831420Q50579666-BC88EB3C-30DB-4152-B82C-E4441029886BQ51694730-A3EEE845-9C13-422D-B337-73FDBC50F958Q51727055-63F9A2E8-6991-4F0B-A407-B539EA87B5E6Q51990664-72D75DBC-B462-4AEE-90CE-DF314C3BA1A5Q56978335-6CDF09CE-0CD4-4E4E-BAD0-38B3D811E99CQ57612823-E7C85CC6-67C8-4A52-895F-4C7722C57036Q58854409-1B205415-D573-45B7-9C87-B194BB02C6F3Q58854416-7A0AB9BC-166B-4482-82B1-8E993C2AAB62Q59413171-1F8C3A56-6DD4-4797-B5AD-11E3135AF84DQ60528278-2864EDC8-1655-4A9C-B5C1-3A35B157883E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anne Laure Fauchais
@ast
Anne Laure Fauchais
@en
Anne Laure Fauchais
@es
Anne Laure Fauchais
@nl
Anne Laure Fauchais
@sl
type
label
Anne Laure Fauchais
@ast
Anne Laure Fauchais
@en
Anne Laure Fauchais
@es
Anne Laure Fauchais
@nl
Anne Laure Fauchais
@sl
prefLabel
Anne Laure Fauchais
@ast
Anne Laure Fauchais
@en
Anne Laure Fauchais
@es
Anne Laure Fauchais
@nl
Anne Laure Fauchais
@sl
P106
P1153
7004138721
P21
P31
P496
0000-0002-0489-8570